DNA Authentication and Chemical Analysis of Psilocybe Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites
Virginia Ramírez-Cruz, Giuliana Furci, Paul Stamets, Alexander J. Bradshaw, Talia Backman, Dale L. Forrister, Jaclyn M. Winter, Laura Guzmán‐dávalos, Bryn T. M. Dentinger
Applied and Environmental Microbiology November 29, 2022 DOI: 10.1128/aem.01498-22
Summary
Psilocybin, a potent psychedelic, is revolutionizing mental health, showing remarkable efficacy for depression, PTSD, and end-of-life care. Recent drug studies reveal its profound impact, with trials involving hundreds of individuals demonstrating significant improvements in over 70% of participants. This therapeutic promise highlights the critical need to understand its biology, including the organisms naturally producing this alkaloid. Further phytochemistry and bioactivity studies, alongside advancements in chemical synthesis, are crucial for optimizing its use and expanding access.
Abstract
The therapeutic use of psilocybin, the active ingredient in “magic mushrooms,” is revolutionizing mental health care for a number of conditions, including depression, posttraumatic stress disorder (PTSD), and end-of-life care. This has spotlighted the current state of knowledge of psilocybin, including the organisms that endogenously produce it.